Inclusion Criteria:

- Female patients, >/=18 years of age

- Histologically confirmed epithelial ovarian carcinoma, fallopian tube carcinoma,
primary peritoneal carcinoma or clear cell carcinoma or carcinosarcoma. Patients with
recurrent ovarian cancer who have been previously treated with surgery alone for
their early stage disease are eligible.

- Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0, 1 or 2

- Life expectancy >/=3 months

Exclusion Criteria:

- Patients with non-epithelial ovarian cancer, ovarian tumors with low malignant
potential (i.e. borderline tumors), or synchronous primary endometrial carcinoma

- Previous systemic therapy for ovarian cancer. Prior neo-adjuvant chemotherapy is
allowed

- Planned intraperitoneal cytotoxic chemotherapy

- Radiotherapy within 28 days of Day 1, Cycle 1

- Major surgical procedure, open biopsy or significant traumatic injury within 28 days
prior to first dose of Avastin

- History or evidence of NCI CTAE Grade >/=1 arterial thromboembolic event or Grade
>/=3 venous thromboembolic event within 6 months prior to enrolment